about
Lithium: the pharmacodynamic actions of the amazing ionStructural elucidation of the binding site and mode of inhibition of Li(+) and Mg(2+) in inositol monophosphataseHow does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.Standards of lithium monitoring in mental health Ttrusts in the UKThyroid Function and Ultrasonography Abnormalities in Lithium-Treated Bipolar Patients: A Cross-sectional Study with Healthy Controls.Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?Trace elements in glucometabolic disorders: an update.Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents.Thyroid functions and bipolar affective disorder.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.Subthreshold bipolarity: diagnostic issues and challengesSinus Node Dysfunction After Acute Lithium Treatment at Therapeutic Levels.Spectrum of lithium induced thyroid abnormalities: a current perspective.Lithium-induced sinus node dysfunction at therapeutic levels.Lithium-induced sinus node disease at therapeutic concentrations: linking lithium-induced blockade of sodium channels to impaired pacemaker activity.NR2B subunit of the NMDA glutamate receptor regulates appetite in the parabrachial nucleusWnt signaling during fracture repairThyroid dysfunction in major psychiatric disorders in a hospital based sample.Wnt and the Wnt signaling pathway in bone development and disease.Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy.The science and practice of lithium therapy.Endocrine disturbances related to the use of lithium.LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice.Improving lithium therapeutics by crystal engineering of novel ionic cocrystals.Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients.Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Lithium-induced transient euthyroid hyperthyroxinemia: a case report.Potentiation of Endocrine Adverse Effects of Lithium by Enalapril and Verapamil.Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.Ketamine followed by memantine for the treatment of major depression.Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management.How Trace Element Levels of Public Drinking Water Affect Body Composition in Turkey.Lithium Treatment Aggregates the Adverse Effects on Erythrocytes Subjected to Arsenic Exposure.Staying at the crossroads: assessment of the potential of serum lithium monitoring in predicting an ideal lithium dose.Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism
P2860
Q22241779-A5E7F112-028C-42B8-B010-A86A280051FEQ27695661-E328CF07-27C3-42D6-825B-FCB9C888BF03Q33602939-61BCD767-94AB-4B4D-B004-69D75D670024Q33702416-130D03CC-AD25-41C0-8013-A43C6DF2D91DQ33715759-F0DC4141-0A22-4109-9C3D-A1A13AB4C2EDQ33854877-CC7C4506-E7FF-4D80-8401-D4E10EA27346Q34503303-0729B7B6-063A-4A47-9EC7-E85AE8155663Q34504189-4489D4BA-C5A4-4AD9-9069-01ACF7E4B43CQ34543946-A8215A39-04D2-44E9-98FB-358A98A65FE3Q34598000-25E4245D-6A63-432D-A5A1-4B4E38AA4D3CQ35130991-D0FEB958-44F9-46E5-B22C-8449C8521AD1Q35560309-2F2A74D9-1809-4142-9C9A-2FE9827B9345Q36096615-FFA61C8E-3409-4AB4-A871-411949C27C91Q36588842-5BC45E99-6CAD-4CAB-A8C9-EDA6559540C2Q36599475-E03CCAFB-5B82-4657-AE86-6887CEB80DA3Q36703683-5162CFC6-0D76-49BA-BC77-72E43F3404F6Q36755384-0DFD4080-28D3-4046-84EA-5259C404A051Q37157389-8C8762FB-7556-49CC-8D89-128C8F9C71A9Q37561706-620C713A-E0A4-4D1B-A1B1-2D32EF77279BQ37690833-9BEE38AB-5623-4A68-AF69-371D0F88CC5FQ37724188-60EFB74C-0D4F-4F7C-9696-EE5ACBCD606FQ37924185-E8152975-D2EB-4B4D-9791-A0CAF3657CBFQ37990676-B03E3FEE-5187-41B2-ABC0-578B7AD15A5BQ38016176-D8974C25-4FE7-46CE-8426-1C48AF4904D0Q38724561-D4C2956B-1FC2-4FF8-9A39-93D26F78D6D8Q39066912-0ECB1252-B245-427F-95D8-3E0931C3A50CQ39152568-21AA2B4C-390B-4C31-A35A-F890ADB9EF61Q39161509-2805B79F-D4F9-41E7-9F74-73B2F673F806Q39404106-73114A5A-23BC-4DB2-8B67-7DCC9C0206F5Q42286640-FEC03B54-C846-42FB-8904-2B6B081E6F2CQ43144278-78A0E1B1-E3A9-4D50-9F4A-9BB3CF2C7DF5Q43254867-06344484-D40E-495D-955F-931461BE1069Q46806781-273EF3EA-3DE3-4232-9562-5F302096CD57Q47279229-6F54FB1D-8413-4BA8-9848-08DF58264302Q47616753-65841FFF-4EBF-44AB-A482-871A1D840DF2Q47853128-35B8BE1C-890C-4497-AD60-0A680708569BQ48895126-223B0953-E2ED-4CA3-B863-68ECBCFF74CBQ57213107-F3BA4E0D-F294-4CF5-BB50-11AB22C44B3B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Lithium: a review of its metabolic adverse effects.
@ast
Lithium: a review of its metabolic adverse effects.
@en
type
label
Lithium: a review of its metabolic adverse effects.
@ast
Lithium: a review of its metabolic adverse effects.
@en
prefLabel
Lithium: a review of its metabolic adverse effects.
@ast
Lithium: a review of its metabolic adverse effects.
@en
P2860
P356
P1476
Lithium: a review of its metabolic adverse effects.
@en
P2093
Callum Livingstone
Hagan Rampes
P2860
P304
P356
10.1177/0269881105057515
P407
P577
2005-09-20T00:00:00Z